Treatment of venous thromboembolism in cancer patients: The dark side of the moon

2021 ◽  
Vol 96 ◽  
pp. 102190
Author(s):  
Cecilia Becattini ◽  
Marcello Di Nisio ◽  
Laura Franco ◽  
Agnes Lee ◽  
Giancarlo Agnelli ◽  
...  
Keyword(s):  
Venous Thromboembolism ◽  
Cancer Patients ◽  
Dark Side ◽  
The Moon

scholarly journals Nasopharyngeal swab or clinical-radiological evidence: the dark side of the moon for cancer patients in the COVID-19 era

2020 ◽  
Vol 16 (19) ◽  
pp. 1321-1322 ◽  
Author(s):  
Antonello Veccia ◽  
Stefania Kinspergher ◽  
Mariachiara Dipasquale ◽  
Orazio Caffo
Keyword(s):  
Cancer Patients ◽  
Dark Side ◽  
Nasopharyngeal Swab ◽  
The Moon ◽  
Radiological Evidence

Treatment and secondary prevention of venous thromboembolism in cancer patients

2012 ◽  
Vol 03 (03) ◽  
pp. 121-125
Author(s):  
I. Pabinger ◽  
C. Ay
Keyword(s):  
Clinical Trials ◽  
Venous Thromboembolism ◽  
Cancer Patients ◽  
Oral Anticoagulants ◽  
Factor Xa ◽  
New Oral Anticoagulants ◽  
Phase Iii ◽  
Patients With Cancer ◽  
Potential Use

SummaryCancer is a major and independent risk factor of venous thromboembolism (VTE). In clinical practice, a high number of VTE events occurs in patients with cancer, and treatment of cancerassociated VTE differs in several aspects from treatment of VTE in the general population. However, treatment in cancer patients remains a major challenge, as the risk of recurrence of VTE as well as the risk of major bleeding during anticoagulation is substantially higher in patients with cancer than in those without cancer. In several clinical trials, different anticoagulants and regimens have been investigated for treatment of acute VTE and secondary prophylaxis in cancer patients to prevent recurrence. Based on the results of these trials, anticoagulant therapy with low-molecular-weight heparins (LMWH) has become the treatment of choice in cancer patients with acute VTE in the initial period and for extended and long-term anticoagulation for 3-6 months. New oral anticoagulants directly inhibiting thrombin or factor Xa, have been developed in the past decade and studied in large phase III clinical trials. Results from currently completed trials are promising and indicate their potential use for treatment of VTE. However, the role of the new oral thrombin and factor Xa inhibitors for VTE treatment in cancer patients still has to be clarified in further studies specifically focusing on cancer-associated VTE. This brief review will summarize the current strategies of initial and long-term VTE treatment in patients with cancer and discuss the potential use of the new oral anticoagulants.

The Dark Side Of The Moon: Nocebo Effects In Medicine

2018 ◽  
Author(s):  
Paul Enck ◽  
Sibylle Klosterhalfen
Keyword(s):  
Dark Side ◽  
The Moon ◽  
Nocebo Effects

scholarly journals Risk of venous thromboembolism in cancer patients treated with epoetins or blood transfusions

2016 ◽  
Vol 82 (3) ◽  
pp. 839-848 ◽  
Author(s):  
Antonios Douros ◽  
Kathrin Jobski ◽  
Bianca Kollhorst ◽  
Tania Schink ◽  
Edeltraut Garbe
Keyword(s):  
Venous Thromboembolism ◽  
Cancer Patients ◽  
Blood Transfusions

scholarly journals Current management of cancer-associated venous thromboembolism in patients with thrombocytopenia: a retrospective cohort study

2021 ◽  
Author(s):  
Alessandro Squizzato ◽  
Silvia Galliazzo ◽  
Elena Rancan ◽  
Marina Di Pilla ◽  
Giorgia Micucci ◽  
...  
Keyword(s):  
Platelet Count ◽  
Venous Thromboembolism ◽  
Cancer Patients ◽  
Cerebral Metastasis ◽  
Bleeding Complications ◽  
Severe Thrombocytopenia ◽  
Regression Analyses ◽  
Multivariate Logistic Regression ◽  
Current Management

AbstractOptimal management of venous thromboembolism (VTE) in cancer patients with thrombocytopenia is uncertain. We described current management and clinical outcomes of these patients. We retrospectively included a cohort of cancer patients with acute VTE and concomitant mild (platelet count 100,000–150,000/mm3), moderate (50,000–99,000/mm3), or severe thrombocytopenia (< 50,000/mm3). Univariate and multivariate logistic regression analyses explored the association between different therapeutic strategies and thrombocytopenia. The incidence of VTE and bleeding complications was collected at a 3-month follow-up. A total of 194 patients of whom 122 (62.89%) had mild, 51 (26.29%) moderate, and 22 (11.34%) severe thrombocytopenia were involved. At VTE diagnosis, a full therapeutic dose of LMWH was administered in 79.3, 62.8 and 4.6% of patients, respectively. Moderate (OR 0.30; 95% CI 0.12–0.75), severe thrombocytopenia (OR 0.01; 95% CI 0.00–0.08), and the presence of cerebral metastasis (OR 0.06; 95% CI 0.01–0.30) were independently associated with the prescription of subtherapeutic LMWH doses. Symptomatic VTE (OR 4.46; 95% CI 1.85–10.80) and pulmonary embolism (OR 2.76; 95% CI 1.09–6.94) were associated with the prescription of full therapeutic LMWH doses. Three-month incidence of VTE was 3.9% (95% CI 1.3–10.1), 8.5% (95% CI 2.8–21.3), 0% (95% CI 0.0–20.0) in patients with mild, moderate, and severe thrombocytopenia, respectively. The corresponding values for major bleeding and mortality were 1.9% (95% CI 0.3–7.4), 6.4% (95% CI 1.7–18.6), 0% (95% CI 0.0–20.0) and 9.6% (95% CI 5.0–17.4), 48.2% (95% CI 16.1–42.9), 20% (95% CI 6.6–44.3). In the absence of sound evidence, anticoagulation strategy of VTE in cancer patients with thrombocytopenia was tailored on an individual basis, taking into account not only the platelet count but also VTE presentation and the presence of cerebral metastasis.

The genetics of drug-related movement disorders (DRMD), reply to comment: Antipsychotic-induced catatonia and neuroleptic malignant syndrome: The dark side of the moon

2021 ◽  
Author(s):  
Nadine C. van der Burg ◽  
Asmar F. Y. Al Hadithy ◽  
Peter N. van Harten ◽  
Jim van Os ◽  
P. Roberto Bakker
Keyword(s):  
Neuroleptic Malignant Syndrome ◽  
Movement Disorders ◽  
Dark Side ◽  
The Moon

Effectiveness of a multidisciplinary care program for the management of venous thromboembolism in cancer patients: a pilot study

2021 ◽  
Author(s):  
Ilham Benzidia ◽  
Benjamin Crichi ◽  
Claire Montlahuc ◽  
Hanadi Rafii ◽  
Arlette N’Dour ◽  
...  
Keyword(s):  
Venous Thromboembolism ◽  
Pilot Study ◽  
Cancer Patients ◽  
Care Program ◽  
Multidisciplinary Care
Sign in / Sign up

Export Citation Format

Share Document